Home / Themes / Infra Built in ZIRP '25: HC Platforms
Infra Built in ZIRP '25: HC Platforms
Last updated
Theme thesis · 3/5 sections · Tickers 1 with notes · 5 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsAs of Spring 2025, the investment thesis for the "Infra Built in ZIRP: HC Platforms" subtheme, including GH (Guardant Health) and EXAS (Exact Sciences), is bull
Thesis
As of Spring 2025, the investment thesis for the "Infra Built in ZIRP: HC Platforms" subtheme, including GH (Guardant Health) and EXAS (Exact Sciences), is bullish. These companies have leveraged the infrastructure and technological advancements made during the era of zero interest rate policy (ZIRP) to establish strong operational moats in the healthcare diagnostics sector. This foundational strength allows them to capitalize on the growing demand for innovative cancer screening and diagnostics in a post-ZIRP environment, positioning them well for sustained growth.
Bull case
Both GH and EXAS have developed extensive technological platforms and data networks during the ZIRP era, which are now yielding efficiencies and cost advantages over competitors.
The shift towards personalized medicine and early cancer detection is driving increased demand for advanced diagnostic solutions, favoring companies with established infrastructures like GH and EXAS.
These companies are reporting strong financial performance, with revenue growth and profitability exceeding pre-pandemic levels, indicating successful adaptation to the current market environment.
Bear case
The transition from ZIRP to a higher interest rate environment increases borrowing costs, potentially impacting future R&D investments and growth initiatives for GH and EXAS.
Competition in the healthcare diagnostics space is intensifying, with new entrants potentially challenging the incumbents' market share and pricing power.
Regulatory changes and reimbursement rates could adversely affect the profitability of diagnostic tests, posing a risk to companies heavily reliant on such revenue streams.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| CMS reimbursement updates | Real-time | Understanding policy environment | Google_Sheets |
| Gross Margin on Testing | Quarterly | Tracks lab efficiency and pricing strength. Should expand as scale increases and fixed lab costs get absorbed. | Google_Sheets |
| Test Volume & ASP | Quarterly | Most direct read on adoption and pricing power. Volume + stable or rising ASP = platform scaling well. | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| GH_eb277c45 | mid-2026 | 2026-05-01 | 2026-06-30 | NovaSeq X transition for Guardant360 liquid tests; cost per test expected to drop and gross margins to improve toward the low-to-mid 70% range. | Margin improvement and cost efficiency could meaningfully enhance profitability and free cash flow in 2026 and beyond. | Ticker | 2026-02-19 | earnings_transcript | GH (ticker) |
| GH_551c816d | in 2026 | 2026-01-01 | 2026-12-31 | Launch of Guardant Reveal Ultra, the tumor-informed MRD/therapy monitoring test, expected to ship this year. | Could drive higher oncology volumes and strengthen Guardant360/Reveal synergy, improving growth prospects and competitive moat. | Ticker | 2026-02-19 | earnings_transcript | GH (ticker) |
| GH_a329742a | pending FDA approval; timing to be determined (2026 or later) | 2026-01-01 | 2027-12-31 | Guardant360 Liquid CDx launch following FDA approval. | Adds a concurrent CDx option, potentially expanding addressable market and cross-sell; regulatory milestone risk. | Ticker | 2026-02-19 | earnings_transcript | GH (ticker) |
| GH_17aaaacc | near term (2026) | 2026-01-01 | 2026-12-31 | ACS guideline inclusion for Shield; near-term potential to expand payer coverage and physician adoption. | Could drive Shield volumes and broaden market access, supporting volume growth. | Ticker | 2026-02-19 | earnings_transcript | GH (ticker) |
| GH_4e822abd | 2026–2027 timeframe | 2026-07-01 | 2027-12-31 | AstraZeneca SERENA-6 trial results; potential to drive ESR1 monitoring adoption and Guardant360 volumes if positive. | Positive SERENA-6 results could accelerate therapy-monitoring use and overall Guardant360 demand; risk to sentiment if results are negative. | Ticker | 2026-02-19 | earnings_transcript | GH (ticker) |
Constituents
- GHT2— Guardant Health, Inc.
- DOCST3· no notes yet
- EXAST3· no notes yet
- GDRXT3· no notes yet
- OPRXT3· no notes yet
- VEEVT3· no notes yet